A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin-Reference-Cited by-同舟云学术

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

Published:2014-11-19 Issue:263 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Xia Yifeng¹,Liu Yi-Liang²,Xie Yonghua³,Zhu Wei²,Guerra Francisco²,Shen Shen¹,Yeddula Narayana¹,Fischer Wolfgang⁴,Low William⁴,Zhou Xiaoying³,Zhang Yonghui³⁵⁶,Oldfield Eric²⁷,Verma Inder M.¹

Affiliation:

1. Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

2. Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

3. Department of Pharmacology & Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, P.R. China.

4. Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

5. Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, P.R. China.

6. Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China.

7. Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

Abstract

Lipophilic bisphosphonates combined with rapamycin inhibit the growth of KRAS -mutant lung adenocarcinomas in mouse models.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference49 articles.

1. Role of Tyrosine Kinase Inhibitors in Lung Cancer

2. Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

4. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

5. ras oncogenes in human cancer: A review.;Bos J. L.;Cancer Res.,1989

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of DUSP18 impairs cholesterol biosynthesis and promotes anti-tumor immunity in colorectal cancer;Nature Communications;2024-07-12

2. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways;Cell Biochemistry and Function;2024-06

3. Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets;Nature Reviews Cancer;2024-02-29

4. Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects;Nucleic Acids Research;2023-03-15

5. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target;Clinical and Translational Medicine;2023-01